Non–Small-Cell Lung Cancer
Role of the Immune System and Potential for Immunotherapy

David P. Carbone, MD, PhD,* David R. Gandara, MD,† Scott J. Antonia, MD, PhD,‡ Christoph Zielinski, MD,§ and Luis Paz-Ares, MD, PhD||

Abstract: As the leading cause of cancer death worldwide, lung cancer continues to impose a major burden on healthcare systems and cause significant challenges for clinicians and patients. Most patients present with advanced disease at the time of diagnosis and have a poor prognosis, with the vast majority surviving less than 5 years. Although new therapies have been introduced in recent years that target molecular disease drivers present in a subset of patients, there is a significant need for treatments able to improve response and extend survival while minimizing effects on quality of life. Recent evidence of clinical efficacy for immunotherapeutic approaches for lung cancer suggests that they will become the next major therapeutic advance for this disease. Non–small-cell lung cancer, which accounts for approximately 85% of lung cancer cases, has historically been considered a nonimmunogenic disease; however, as with several other malignancies, recent data show that much of this lack of immune responsive-ness is functional rather than structural (i.e., possible to overcome therapeutically). This review explores the key elements of the immune system involved in non–small-cell lung cancer and briefly examines immunotherapeutic strategies in development to shift the balance of immune activity away from a tumor-induced immune-suppressive state toward an active antitumor immune response.

Key Words: Non–small-cell lung cancer, Immune system, Immunotherapy, Checkpoint inhibitors, Cancer vaccines.

(J Thorac Oncol. 2015;10: 974–984)

*Ohio State University Medical Center, Columbus, Ohio; †University of California Davis Comprehensive Cancer Center, Sacramento, California; ‡H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida; §Comprehensive Cancer Center, Medical University of Vienna General Hospital, Vienna, Austria; and ||Instituto de Biomedicina de Sevilla, Seville, Spain.

Disclosure: David P. Carbone was a paid consultant for Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Genentech, Novartis, and Pfizer, and is currently receiving research grants from Bristol-Myers Squibb. David R. Gandara is currently receiving research grants from Bristol-Myers Squibb and Merck. Scott J. Antonia is currently a paid consultant for Bristol-Myers Squibb and is currently receiving research grants from MedImmune. Luis Paz-Ares is currently a paid consultant for Bristol-Myers Squibb. Christoph Zielinski is an ongoing paid consultant for Bristol-Myers Squibb. No financial support or compensation was received by the authors for this publication.

Address for correspondence: David P. Carbone, MD, PhD, James Thoracic Center and James Cancer Center, Ohio State University Medical Center, 488 Biomedical Research Tower, 460 West 12th Avenue, Columbus, OH 43210. E-mail: david.carbone@osumc.edu

DOI: 10.1097/JTO.0000000000000551
Copyright © 2015 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/15/1007-0974

Lung cancer is the leading cause of cancer-related death worldwide, claiming an estimated 1.59 million lives in 2012.1 Non–small-cell lung cancer (NSCLC) is the predominant form of the disease, accounting for approximately 85% of cases.2 The majority of patients present with locally advanced or metastatic disease, and many do not survive more than 5 years beyond diagnosis.2,3 Although targeted therapy has produced real benefit for specific molecular subtypes of NSCLC, traditional chemotherapy, which usually provides short-lived benefit, remains the only option for most patients. Consequently, there remains a major need for therapy that significantly extends patient survival without compromising quality of life.

In recent years, there has been an increasing recognition of the role of the immune system in cancer development and progression,4–6 with a corresponding focus on utilizing immunotherapy in the clinic and regulatory approvals of immunotherapy for renal cell cancer (interleukin [IL]-2 and interferon-α), prostate cancer (sipuleucel-T®), and melanoma (ipilimumab,8 nivolumab,10 pembrolizumab11). Although NSCLC has historically been considered a nonimmunogenic disease, emerging evidence has demonstrated that the lack of an effective immune response is in fact often the result of specific, active immune-evasive mechanisms, which if understood can be overcome therapeutically with significant clinical efficacy. Harnessing this potential has therefore become a primary area of clinical interest.12–14 Given the increasing understanding of the role of immunology in oncology, this article examines the key elements of the immune system involved in cancer in general and in NSCLC specifically, and briefly outlines some of the immunotherapeutic strategies currently being developed to improve patient outcomes.

THE IMMUNE SYSTEM AND CANCER

The Antitumor Immune Response

The immune system is now recognized to have the potential to destroy cancer cells and inhibit tumor growth through responses elicited by its innate and adaptive arms.15 Innate immune responses are antigen nonspecific, develop quickly, and are mediated by various effector cells (natural killer [NK] cells, polymorphonuclear leukocytes, and mast cells, as well as antigen-presenting cells [APGs], such as macrophages and dendritic cells [DCs]), which lead to the secretion of interferon gamma (IFN-γ) and perforin, as well as inflammatory...
cytokines that induce apoptosis of tumor cells. In contrast, adaptive immune responses are antigen specific, develop more slowly, offer immune memory, and comprise both humoral and cellular immunity mediated by B and T cells, respectively. In this respect, adaptive rather than innate immunity offers the greatest potential for durable, robust anticancer immune responses. Of note, some of the cells involved in innate immunity, such as DCs, macrophages, and NK cells, also play a role in adaptive immunity.

The adaptive anticancer immune response is initiated by immature DCs, which are found in most human tumors and are capable of capturing antigens released from cancer cells (Fig. 1). After maturation (activation), DCs present tumor antigens within major histocompatibility complex (MHC) molecules to naïve T cells in the tumor-draining lymph nodes, triggering a protective T-cell response composed of specific CD4+ helper T (Th) cells and CD8+ cytotoxic T cells. T-cell activation requires interaction not only between the antigen–MHC complex on DCs and T-cell receptors but also among an array of co-stimulatory molecules, including CD80/86 on DCs and the CD28 receptor on T cells. After infiltrating the tumor, activated Th cells secrete cytokines that induce inflammation and recruit other immune cell populations to the tumor microenvironment to eliminate cancer cells. DCs may also induce B-cell-mediated antibody responses and NK cell activity.

Promotion of Tumor Growth by the Immune System

Insights into cellular and molecular immunologic processes have revealed that the immune system is capable of not only inhibiting but also promoting tumor growth, through either the selection of tumor cells that are better able to survive in an immunocompetent host or the creation of conditions within the tumor microenvironment that facilitate tumor growth. It has been proposed that this dual host-protective and tumor-promoting role results from a dynamic relationship between cancer cells and the immune system termed “immunodediting,” which consists of three distinct phases: elimination, equilibrium, and escape (Fig. 2). Early evidence suggested that premalignant clones expressing novel somatic mutant epitopes (immunogenic portions of antigens) might be targeted by the immune system in the initial stages of tumor development. Tumor clones that escape the elimination phase remain dormant in the subsequent equilibrium phase, during which tumor growth does not occur but the immunogenicity of the tumor cells continues to be shaped by selective immune pressure from the adaptive immune response. In time, changes arising in the tumor cell population caused by this selective pressure and/or changes in the immune system as a result of prolonged tumor-mediated immunosuppression may lead to immune escape and tumor growth.

Tumor cells entering the immune escape phase are able to create an immunosuppressive state within the tumor microenvironment by subverting the same mechanisms that under normal conditions help regulate the immune response and prevent damage to healthy tissue. Key immunosuppressive cell types found in the tumor microenvironment are regulatory T (Treg) cells, myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages. Treg cells, which are positive for CD4, CD25, and the Foxp3 transcription factor, suppress the function and proliferation of tumor-specific CD4+ and CD8+ T cells and NK cells, whereas MDSCs induce Treg cells and limit effector T-cell proliferation by means of the production of various immunosuppressive molecules. Tumor-associated macrophages and stromal cells may also secrete cytokines that inhibit an adaptive immune response, such as IL-10 and transforming growth factor-β (TGF-β). In addition, both tumor cells and other cells present in the tumor microenvironment may express the immunosuppressive enzyme indoleamine-2,3-dioxygenase, which depletes the amino acid tryptophan.

**FIGURE 1.** Adaptive anticancer immunity. The adaptive anticancer immune response is initiated by immature DCs, which capture and process tumor antigens. DCs subsequently undergo maturation and migrate to tumor-draining lymph nodes, where they present tumor antigens within MHC molecules to naïve T cells, triggering a protective T-cell response. T-cell activation requires interaction not only between the antigen–MHC complex on DCs and TCRs but also among an array of co-stimulatory molecules, including CD80/86 on DCs and the CD28 receptor on T cells. The adaptive anticancer immune response culminates with the infiltration of activated cytotoxic T cells into the tumor, killing cancer cells. DC, dendritic cell; MHC, major histocompatibility; TCR, T-cell receptor.
(essential for T-cell function), increases local T<sub>r</sub> populations, and induces tumor-specific T-cell deactivation.<sup>20</sup>

Even if T cells can otherwise be activated, specific physiologic regulatory mechanisms, or “checkpoints,” which play a key role in maintaining normal self-tolerance and limiting the extent of immune responses to infection, can be exploited by tumors as immune resistance mechanisms.<sup>21</sup> Two of the most investigated checkpoint receptors in terms of immunotherapeutic targets for cancer are cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) receptor, which downregulate T-cell activation, proliferation, and function through different mechanisms.

CTLA-4 is expressed on the surface of T cells after activation and shares the same ligands (CD80/86 expressed by APCs) as the co-stimulatory T-cell CD28 receptor, which is required for T-cell activation (Fig. 3A).<sup>21</sup> By virtue of its higher affinity for these ligands, CTLA-4 competes with the CD28 receptor in binding to CD80/86, thereby providing an inhibitory signal to the T cell and serving as a negative feedback loop for T-cell activation. In the cancer setting, inhibiting the T-cell response through the CTLA-4 pathway favors tumor survival over elimination. CTLA-4 is also constitutively expressed by T<sub>r</sub> cells and has a critical effect on the ability of these cells to regulate antitumor immunity.<sup>22</sup>

The PD-1 pathway is also an important mechanism by which tumors develop immune resistance (Fig. 3B).<sup>15,21</sup> Upregulation of the PD-1 receptor on activated T cells and subsequent binding to one of its ligands, programmed death ligand-1 (PD-L1) or PD-L2, provide an inhibitory signal during the effector phase of the T-cell response, reducing...
cytokine production, cell proliferation, and cell survival signaling. PD-1 is also expressed at high levels on T<sub>reg</sub> cells, enhancing their proliferation in the presence of a PD-1 ligand. In addition, PD-1 may be induced on activated NK cells, thereby limiting their lytic activity. Present on a wide variety of hematopoietic and nonhematopoietic cells, PD-L1 and PD-L2 are also usually expressed on tumor cells.21,22 Although the clinical significance of PD-L1 expression on tumor cells is yet to be fully characterized, it is thought to confer a survival advantage to the tumor through the PD-1 pathway.17 PD-L1 tumor cell expression is induced by means of IFN-γ secreted by infiltrating Th cells as part of an adaptive immune resistance mechanism.20 Recent evidence shows that the induction of tumor PD-L1 expression can also be upregulated by oncogenic signaling intrinsic to the tumor cells themselves.24

In addition to immunosuppressive mechanisms that undermine antitumor immunity, chronic inflammation can paradoxically promote tumor growth.25 In fact, chronically activated leukocytes produce a range of molecules that can directly stimulate tumor growth, including epidermal growth factor, TGF-β, and tumor necrosis factor alpha. The development of this chronic inflammatory environment also confers a survival advantage to tumor cells by increasing the chance of DNA damage and accumulation of oncogenic mutations.

ROLE OF THE IMMUNE SYSTEM IN NSCLC

The Immunosuppressive NSCLC Tumor Microenvironment

Like other tumor types, NSCLC can establish an immunosuppressive tumor microenvironment conducive to tumor growth.12–14 For instance, NSCLC tumors have been shown to contain large numbers of T<sub>reg</sub> cells that constitutively express high levels of CTLA-4 on their surface and directly inhibit T-cell proliferation.26,27 In addition, in NSCLC, tumor-infiltrating CD8<sup>+</sup> T cells have shown increased PD-1 expression that was associated with impaired immune function.28 PD-L1 expression has also been found to be upregulated on NSCLC tumor cells29 and shown to correlate with the suppression of maturation of tumor infiltrating DCs30 and reduced tumor T-cell infiltration.31 Furthermore, dysfunction of the antigen-presentation apparatus appears to impair immunologic activity in the tumor microenvironment, as lung tumor cells can downregulate surface expression of MHC class I/tumor antigen expression, thereby helping these cells to evade the immune system.32 Lung tumor cells may also release immune suppressive cytokines, including IL-10 and TGF-β.33

Immune Correlates of Clinical Outcome in NSCLC

Further underscoring the involvement of the immune system in NSCLC, a number of immune correlates of clinical outcome in patients with NSCLC have been identified. One of the most remarkable pieces of clinical evidence for immune system involvement in NSCLC is the presence of “preformed” antitumor T cells and antibodies in the blood of patients with NSCLC.34,35 Moreover, tumor-infiltrating lymphocytes (TILs), composed mainly of CD8<sup>+</sup> T cells, were significantly associated with improved survival and correlated with tumor grade, size, vascular invasion, and poor levels of differentiation among patients with NSCLC.36 The presence of TILs has also been linked with a better survival outcome in NSCLC at an early stage as well as a reduced risk of systemic recurrence.37 In separate studies, high levels of infiltrating CD8<sup>+</sup> T cells, both CD8<sup>+</sup> and CD4<sup>+</sup> T cells, and T cells expressing the pan T-cell marker CD3,38,39 as well as higher densities of mature DCs in tertiary lymphoid structures,21 have been associated with improved survival. Conversely, the number of T<sub>reg</sub> cells40 and higher numbers of macrophages with protumor functions41 in NSCLC tumors have been shown to be independent predictors of reduced survival. PD-L1 expression on tumor cells also correlates with an unfavorable prognosis in patients with NSCLC.23,29,30 Finally, high activity levels of nuclear factor kappa-light-chain-enhancer of activated B cells, a transcription factor constitutively activated in many tumor types, have been associated with the recruitment and infiltration of antitumor T cells into tumor tissue and extended survival in patients with NSCLC.45

DEVELOPMENT OF IMMUNOTHERAPY FOR NSCLC

Given the clear role of the immune system in NSCLC, research efforts are being intensively directed toward the development of various immunotherapies for the disease, particularly those promoting adaptive immune responses.12–14 Cancer immunotherapy can be broadly divided into antigen-specific and antigen-nonspecific therapies, with the respective aims of stimulating specific antitumor immunity and influencing steps after the immune system has been previously stimulated. Examples of antigen-specific and antigen-nonspecific immunotherapies include cancer vaccines and immune checkpoint inhibitors, respectively. A number of immunotherapeutic strategies for NSCLC, including those that stimulate immune processes and counteract tumor immune evasion, are being investigated in clinical trials (Table 1).46–59

Immune Checkpoint Inhibitors

Perhaps the most significant advances in NSCLC immunotherapy have been made by targeting immune checkpoint pathways to prevent or reduce tumor-mediated immune suppression. In particular, several monoclonal antibodies that block immune checkpoint pathways, such as those involving PD-1 and CTLA-4, are being investigated in clinical trials with NSCLC (Table 2).47–50,52–55 These immune checkpoint inhibitors offer the advantage of enhancing the host’s own antitumor immune response without regard to the specific tumor antigen, thus conferring broader clinical application than antigen-specific immunotherapies, such as vaccines.12

Nivolumab (BMS-936558; ONO-4538), a fully human immunoglobulin G4 (IgG4) monoclonal antibody directed against PD-1,60 that was approved in 2014 in the United States and Japan for treating patients with advanced melanoma, is being investigated for advanced NSCLC.47 Nivolumab was approved in the United States in 2015 for treating patients with metastatic squamous NSCLC with progression on or after platinum-based chemotherapy.61 In a phase
I study (Table 2), in previously treated patients with advanced NSCLC (n = 129), nivolumab demonstrated an objective response rate (ORR) based on Response Evaluation Criteria In Solid Tumors (RECIST) v1.0 of 17% across all doses evaluated and 24% with 3 mg/kg dose given every 2 weeks (the dose selected for phase III studies), with an estimated median response duration of 74 weeks across all doses and at the 3 mg/kg dose. Across all doses, responses occurred early, with 50% of patients demonstrating a response at 8 weeks, and were ongoing in 45% of patients. Responses occurred in various NSCLC patient subpopulations, including those with squamous and nonsquamous cell histology (17% and 18%), who received less than three and greater than or equal to three prior therapies (12% and 21%), who were less than 70 and greater than or equal to 70 years of age (17% and 18%), and with and without tumors driven by epidermal growth factor receptor (EGFR; 17% and 20%) or Kirsten rat sarcoma oncogene homolog (KRAS) mutations (14% and 25%). Across all doses, median OS was 9.9 months, with 1- and 2-year survival rates of 42% and 24%, respectively. With the 3 mg/kg dose, median OS was 14.9 months, with 1- and 2-year survival rates of 56% and 45%, respectively. Although it is difficult to compare findings between trials, the survival results with nivolumab are promising relative to previous experience with other agents. 

Nivolumab had a manageable safety profile, with the most common treatment-related adverse events (any grade) being fatigue (24%), decreased appetite (12%), and diarrhea (10%). Grade 3-4 treatment-related adverse events occurred in 14% of patients. In another phase I study (CheckMate 012; Table 2), nivolumab showed clinical activity, with a RECIST v1.1-based ORR of 30%, in chemotherapy-naïve patients with advanced NSCLC. In addition, in the same phase I study (CheckMate 012; Table 2), chemotherapy-naïve patients with EGFR-mutant advanced NSCLC achieved a RECIST v1.1-based ORR of 19% with nivolumab plus erlotinib, an EGFR tyrosine kinase inhibitor. Nivolumab also demonstrated clinical meaningful activity (RECIST v1.1-based ORR: 15%) in a phase II, single-arm study (CheckMate 063; Table 2) with patients having advanced, refractory squamous NSCLC (n = 177). Phase III trials are evaluating nivolumab monotherapy versus current standard of care as first-line therapy for squamous and nonsquamous NSCLC (NCT02041533 [CheckMate 026]) or subsequent line of therapy for nonsquamous NSCLC (NCT01673867 [CheckMate 057]). A phase III study (NCT01642004 [CheckMate 017]) evaluating nivolumab versus docetaxel in patients with stage IIIB/IV squamous NSCLC with disease recurrence or progression during or after one prior platinum doublet-based chemotherapy regimen was stopped early because an assessment conducted by the independent Data Monitoring Committee found that the study met its primary end point of superior OS with nivolumab. It should be noted that some of these phase III trials did not select patients for PD-L1 expression and may thus provide an opportunity for its validation as a potential predictive biomarker.

Pembrolizumab (MK-3475), a humanized IgG4 monoclonal antibody directed against PD-1 that was approved in 2014 in the United States for treating patients with advanced or unresectable melanoma who are no longer responding to other agents, is being assessed for NSCLC. In a phase I study (KEYNOTE-001; Table 2) with patients having treatment-naïve and previously treated NSCLC (n = 262), pembrolizumab demonstrated a RECIST v1.1-based ORR of 21%. ORR was higher for patients who were treatment-naïve versus previously treated (26% and 20%, respectively), had nonsquamous versus squamous histology (23% versus 18%, respectively), were current or former versus never smokers (27% versus 9%, respectively), and had tumor with KRAS versus EGFR mutations (39% versus 36%, respectively). Median OS in the treatment-naïve and previously treated cohorts was not
### TABLE 2. Results of Trials of Immune Checkpoint Inhibitors in Clinical Development for the Treatment of Patients with Advanced Non–Small-Cell Lung Cancer

<table>
<thead>
<tr>
<th>Agent (Reference)</th>
<th>Study Design (Study Name)</th>
<th>Number of Patients</th>
<th>Median Follow-Up</th>
<th>Objective Response Rate, % (n/N)</th>
<th>Median (Range) Response Duration, Weeks</th>
<th>Median Progression-Free Survival</th>
<th>Median Overall Survival (Months)</th>
<th>1-Year Survival Rate (%)</th>
<th>2-Year Survival Rate (%)</th>
<th>Incidence of Adverse Events (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nivolumab (Brahmer et al.⁴⁷)</td>
<td>Phase I dose-ranging study of nivolumab (1, 3, and 10 mg/kg IV Q2W) in previously treated patients with advanced solid tumors, including advanced NSCLC (NSCLC cohort)</td>
<td>129 (NSCLC cohort)</td>
<td>27 months</td>
<td>Across all doses: 17 (22 of 129r) 3 mg/kg Q2W dose: 24 (9 of 37)</td>
<td>Across all doses: 2.3 months (95% CI, 1.8–3.7r)</td>
<td>Across all doses: 9.9 (95% CI, 7.8–12.4)</td>
<td>Across all doses: 42 (95% CI, 34–51)</td>
<td>Across all doses: 24 (95% CI, 16–32)</td>
<td>Treatment-related any grade: fatigue, 24; decreased appetite, 12; diarrhea, 10</td>
<td></td>
</tr>
<tr>
<td>Nivolumab (Gettinger et al.⁴⁸)</td>
<td>Phase I multi-cohort study of nivolumab as monotherapy or combined with chemotherapy, targeted therapy, or ipilimumab in chemotherapy-naïve patients with advanced NSCLC (CheckMate 012)</td>
<td>20</td>
<td>66.1 weeks</td>
<td>30 (6 of 20)</td>
<td>NR</td>
<td>36.1 weeks</td>
<td>NR</td>
<td>75 (95% CI, 50–89)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Nivolumab (Rizvi et al.⁴⁹)</td>
<td>Phase I dose-ranging study of nivolumab 3 mg/kg IV Q2W plus erlotinib 150 mg/day PO in nonsquamous EGFR MT cohort treated with nivolumab 3 mg/kg IV Q2W plus erlotinib (CheckMate 012)</td>
<td>21 (nonsquamous EGFR MT cohort treated with nivolumab 3 mg/kg IV Q2W plus erlotinib 150 mg/day PO)</td>
<td>71.9 weeks</td>
<td>19 (4 of 21)</td>
<td>NR</td>
<td>29.4 weeks</td>
<td>NR</td>
<td>73 (95% CI, 46–88)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Nivolumab (Rizvi et al.⁵⁰)</td>
<td>Phase II single-arm study of nivolumab 3 mg/kg IV Q2W in patients with advanced, refractory squamous NSCLC (CheckMate 063)</td>
<td>117</td>
<td>8.0 months</td>
<td>15 (17 of 117)</td>
<td>NR</td>
<td>1.9 months (95% CI, 1.8–3.2)</td>
<td>8.2 (95% CI, 6.1–10.9)</td>
<td>40.8 (95% CI, 31.6–49.7)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Pembrolizumab (Garon et al.⁵¹)</td>
<td>Phase I study of pembrolizumab (2 mg/kg IV Q3W, 10 mg/kg IV Q3W, and 10 mg/kg IV Q2W) with treatment-naïve and previously treated patients with advanced NSCLC (KEYNOTE-001)</td>
<td>262</td>
<td>NA</td>
<td>21 (treatment-naïve patients: 26; previously treated patients: 20)</td>
<td>NA</td>
<td>Treatment-naïve patients: 27 weeks (95% CI, 14–45)</td>
<td>Treatment-naïve patients: NR (95% CI, NE–NE)</td>
<td>Treatment-naïve patients: 8.2 (95% CI, 7.3–NR)</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Agent (Reference)</th>
<th>Study Design (Study Name)</th>
<th>Number of Patients</th>
<th>Median Follow-Up</th>
<th>Objective Response Rate, % (n/N)</th>
<th>Median (Range) Response Duration, Weeks</th>
<th>Median Progression-Free Survival</th>
<th>Median Overall Survival (Months)</th>
<th>1-Year Survival Rate (%)</th>
<th>2-Year Survival Rate (%)</th>
<th>Incidence of Adverse Events (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MPDL3280A (Soria et al.53)</td>
<td>Phase I study of MPDL3280A IV Q3W in patients with squamous or nonsquamous NSCLC</td>
<td>53</td>
<td>NA</td>
<td>24 (9 of 37)</td>
<td>Median was not reported (range: 1+ to 214+ days)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>All-cause grade 3-4: 34 (pericardial effusion, 6; dehydration, 4; dyspnea, 4; fatigue, 4)</td>
</tr>
<tr>
<td>MEDI4736 (Brahmer et al.54)</td>
<td>Phase I dose-escalation dose-expansion study of MEDI4736 (0.1–10mg/kg IV Q2W; 15mg/kg IV Q3W) in patients with advanced solid tumors, including advanced NSCLC</td>
<td>155 (NSCLC cohort)</td>
<td>6 weeks</td>
<td>Across all doses: 16 (9 of 58)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Treatment-related any grade: 29 Treatment-related grade 3-4: 3</td>
<td></td>
</tr>
<tr>
<td>Ipilimumab (Lynch et al.55)</td>
<td>Phase II study of ipilimumab (10mg/kg IV Q3W) plus paclitaxel/carboplatin (concurrent or phased administration) versus paclitaxel/carboplatin (control) in chemotherapy-naïve patients with advanced NSCLC</td>
<td>204</td>
<td>NA</td>
<td>Control: 18 (12 of 66) Concurrent: 21 (15 of 70) Phased: 32 (22 of 68)</td>
<td>Control: 4.6 (HR, 0.81; p = 0.13 versus control) Concurrent: 5.5 (HR, 0.97; p = 0.48 versus control) Phased: 5.7 (HR, 0.72; p = 0.05 versus control)</td>
<td>Control: 8.3 (HR, 0.97; p = 0.48 versus control) Concurrent: 50 Phased: 42</td>
<td>Control: 39 (HR, 0.72; p = 0.05 versus control) Concurrent: 18 (HR, 0.87; p = 0.23 versus control) Phased: 37 (HR, 0.87; p = 0.23 versus control)</td>
<td>Control: 18 (HR, 0.97; p = 0.48 versus control) Concurrent: 41 (HR, 0.87; p = 0.23 versus control) Phased: 39 (HR, 0.87; p = 0.23 versus control)</td>
<td>Treatment-related grade 3-4: 41</td>
<td></td>
</tr>
</tbody>
</table>

*Based on Response Evaluation Criteria In Solid Tumors (RECIST).  
*The nivolumab dose selected for phase 3 studies.  
*Based on irRC.  
CI, confidence interval; EGFR MT, epidermal growth factor receptor mutant; HR, hazard ratio; irPFS, immune-related progression-free survival; NA, not available; NE, not estimable; NR, not reached; NSCLC, non–small-cell lung cancer; PO, oral administration; Q2W, every 2 weeks; Q3W, every 3 weeks; irRC, immune-related response criteria.
reached and 8.2 months, respectively. The most common treatment-related adverse events (any grade) were fatigue (20%), pruritus (9%), arthralgia (8%), decreased appetite (8%), and diarrhea (7%). Grade 3–4 treatment-related adverse events occurred in 9% of patients. A phase II/III study is ongoing comparing two dose levels of pembrolizumab with docetaxel in pretreated patients with advanced NSCLC (NCT01905657 [KEYNOTE-010]). Phase III studies comparing first-line pembrolizumab monotherapy with platinum-based doublet chemotherapy in PD-L1-positive, advanced NSCLC are recruiting patients (NCT02142738 [KEYNOTE-024] and NCT02220894 [KEYNOTE-042]).

Targeting the PD-1 ligand PD-L1 may provide an alternative strategy for NSCLC. In a phase I study (Table 2) with patients with squamous or nonsquamous NSCLC (n = 37), MPDL3280A, a human IgG1 monoclonal antibody directed against with an engineered fragment crystallizable (Fc) domain to prevent antibody-dependent cell-mediated cytotoxicity and complement-dependent cell-mediated cytolysis of tumor-infiltrating T cells meant to be activated,69 achieved an RECIST v1.1-based ORR of 24%.53 ORR was greater in the former or current smokers (25%) than in never smokers (16%). Grade 3–4 adverse events, regardless of attribution, occurred in 34% of patients and included pericardial effusion (6%), dehydration (4%), dyspnea (4%), and fatigue (4%). A phase II study is currently examining the use of MPDL3280A in patients with PD-L1-positive advanced NSCLC (FIR study [NCT01846416]). Phase II and III studies are also underway comparing MPDL3280A with docetaxel among patients with advanced NSCLC who failed previous platinum therapy (POPLAR study [NCT01903993] and OAK study [NCT02008227], respectively).

MEDI4736, a fully human IgG1 monoclonal antibody directed against PD-L1 containing an engineered IgG1 Fc domain to prevent antibody-dependent cell-mediated cytolysis and complement-dependent cell-mediated cytolysis of tumor-infiltrating T cells,69 produced a RECIST v1.1-based ORR of 16% in a phase I study (Table 2) with patients with NSCLC (n = 155), who were mostly pretreated64 and is being further studied in phase II/III studies with patients with NSCLC (Lung-MAP study [NCT02154490] and ATLANTIC study [NCT02087423]).

Research is underway to identify biomarkers that might predict which patients respond best to PD-1 pathway inhibitors, the most promising of which may be the level of PD-L1 expression in the tumor microenvironment. Considering the role of PD-L1 in tumor immune evasion, it is logical to assume that PD-L1 expression would be a viable biomarker.63 In preliminary analyses with various PD-1 pathway inhibitors, expression of PD-L1 on tumor cells at baseline appeared to correlate with increased efficacy.46–48,50,52–54 For example, in the phase II CheckMate 063 study with nivolumab in patients having advanced, refractory squamous NSCLC, RECIST-based ORR was greater in patients with PD-L1-positive tumors (≥5% tumor cells expressing PD-L1 by immunohistochrometry [IHC]) versus PD-L1-negative tumors (24% [6 of 25] versus 14% [7 of 51], respectively).50 Similarly, among treatment-naïve and previously treated patients with advanced NSCLC receiving pembrolizumab in the phase I KEYNOTE-001 trial, ORR by RECIST was greater in patients with PD-L1-positive tumors (≥1% tumor cells expressing PD-L1 by IHC) than in those with PD-L1-negative tumors (23% versus 9%).52 Patients in that study, who were PD-L1 strong-positive (≥50% membranous staining in tumor cells) versus PD-L1 weak-positive or negative demonstrated longer median OS (hazard ratio [HR]: 0.59; 95% confidence interval: 0.35–0.99) and median progression-free survival (HR: 0.52; 95% confidence interval: 0.33–0.80). Expression of PD-L1 on tumor-infiltrating immune cells may also be predictive of response with anti-PD-L1 agents, as suggested in a phase 1 study of MPDL3280A with NSCLC patients showing that RECIST-based ORRs were significantly associated with tumor-infiltrating immune cell PD-L1 expression (p = 0.015).70 PD-L1-positive tumor-infiltrating immune cells included macrophages, DCs, and T cells. In that study, responses occurred in 83% of patients (5 of 6) with an IHC score of three (≥10% of cells per area expressing PD-L1) compared with 20% (4 of 20), 15% (2 of 13), and 14% (1 of 7) of patients with IHC scores of zero (<1% of cells), one (≥1 but <5% of cells), and two (≥5% but <10% of cells), respectively. The conclusions that can be drawn from these analyses, however, are limited by several factors, including small patient numbers due to low rate of tissue sample ascertainment, the use of archival (versus fresh) tumor samples, use of ORR (which may not be the optimal end point to assess the predictive role of biomarkers for immune-based therapies), the dynamic nature of and intratumor variations in PD-L1 expression, the effect of prior treatment on PD-L1 status, lack of standardization of IHC assays, and undefined cutoff values for PD-L1 positivity.23,47,50 The use of PD-L1 as a biomarker is therefore being further explored in larger NSCLC trials.

The fully human IgG1 monoclonal antibody ipilimumab, which is directed against CTLA-4, has shown anti-tumor activity and a survival advantage with advanced melanoma4 and may have potential in treating patients with advanced NSCLC.55 A phase II study (Table 2) compared ipilimumab plus paclitaxel and carboplatin (concurrent or phased administration) with paclitaxel and carboplatin alone (control) in chemotherapy-naïve patients with stage IIIB/IV NSCLC (n = 204).55 In that study, phased administration (paclitaxel and carboplatin followed by ipilimumab plus paclitaxel and carboplatin) demonstrated significantly improved median immune-related progression-free survival (irPFS), the primary study end point, compared with paclitaxel and carboplatin alone (5.7 versus 4.6 months; HR: 0.72; p = 0.05), with greater improvements in irPFS occurring with squamous versus nonsquamous histology. However, concurrent administration (ipilimumab plus paclitaxel and carboplatin followed by paclitaxel and carboplatin) did not significantly improve irPFS versus control. There was a nonstatistical trend toward improved median OS with phased administration compared with control, but not with concurrent administration. Ipilimumab did not seem to impact toxicities associated with paclitaxel and carboplatin. Immune-mediated adverse events (e.g., rash, pruritus, diarrhea) occurred more frequently in the ipilimumab arms than in the control arm. The combination of
ipilimumab with paclitaxel and carboplatin is being further investigated in a phase III study in patients with stage III/IV recurrent squamous NSCLC (NCT01285609).

Interestingly, early results of ipilimumab in combination with nivolumab in melanoma suggest that a two-pronged approach may provide clinical benefit based on the apparently complementary roles of CTLA-4 and PD-1 in negative immune regulation.72 A phase I study is also ongoing to evaluate this combination in treatment-naïve advanced patients with NSCLC (NCT01454102). In addition, MEDI4736 combined with tremelimumab, an IgG2 anti-CTLA-4 antibody, is being investigated in patients with previously treated NSCLC in a phase I study (NCT02000947).72

Overall, immune checkpoint inhibitors that target the PD-1 or CTLA-4 pathways have manageable safety profiles (Table 2).46–50,52–55 These agents are characteristically associated with immune-related adverse events (e.g., rash, pruritus, diarrhea, hypothyroidism, hepatitis), which are consistent with the their mechanism of action and can often be managed with protocol-specified guidelines (e.g., close patient follow-up and early administration of systemic corticosteroids and/or other immunosuppressive agents).23,47,55,69

Agents that inhibit other immune checkpoint pathways may also have potential in treating patients with advanced NSCLC.73 For example, lirilumab (IPH2102), a fully human IgG4 monoclonal antibody that blocks the interaction between killer-cell immunoglobulin-like receptors on NK cells with their ligands,73,74 is being assessed in combination with nivolumab (NCT01714739) or ipilimumab (NCT01750580) in phase I studies with patients with NSCLC. In addition, BMS-986016, a monoclonal antibody that binds to lymphocyte-activation gene 3, a CD4-related immune checkpoint receptor co-expressed with PD-1 on tolerant TILs,74 is being evaluated in combination with nivolumab in patients with advanced solid tumors in a phase I study (NCT01968109).

Although durable clinical responses have been documented in patients with various tumor types treated with immune checkpoint inhibitors, the genetic basis for these benefits is only beginning to be understood. Recent research suggests that patients more likely to achieve meaningful responses to CTLA-4 inhibition have tumors displaying neoantigens, which result from specific somatic mutations harbored by the tumor and elicit an antitumor response augmented by CTLA-4 inhibition.75 Such tumor antigens could be immunogenic and potentially function as targets of T cells activated by immune checkpoint inhibition.76,77 Therefore, methods are being developed for predicting immunogenic tumor mutations, thereby identifying patients who would best benefit from immune checkpoint inhibitors and allowing personalized treatment.77

Cancer Vaccines

Cancer vaccines aim to stimulate the immune system to recognize and respond to one or more tumor antigens, which ideally show exclusive or elevated expression on cancer cells.12 However, as most tumor antigens are closely related or identical to self-antigens and therefore weakly

antigenic, cancer vaccines usually incorporate strong adjuvants to stimulate efficient DC presentation of these proteins.77 A number of cancer vaccines are currently in clinical trials in NSCLC, including tecemotide (liposomal BLP25),56 racotumomab,57 and TG4010,58 which have shown a range of responses and survival outcomes (reviewed in detail elsewhere).12–14 Current evidence suggests that, despite the potential for inducing long-lasting immune memory, vaccine therapy may be most effective in patients with a lower disease burden.13

Non-specific Immune Stimulation

Non-specific immune stimulation has been investigated therapeutically in different cancers, including NSCLC.12 One agent recently evaluated in NSCLC is talactoferrin alfa, a recombinant form of human lactoferrin and an oral DC-mediated immunotherapy that stimulates cytokine release in the intestine, with subsequent recruitment and activation of DCs. However, talactoferrin alfa did not lead to improved OS versus placebo in a phase III study in patients with advanced, pretreated NSCLC.79

CONCLUSIONS

Although traditionally considered a non-immunogenic disease, NSCLC is now recognized to elicit an endogenous immune response. Emerging results with a range of immunotherapeutic agents, such as immune checkpoint inhibitors indicate that this therapeutic modality could eventually have a significant impact upon the survival and quality of life of patients with NSCLC, for whom the outlook is currently bleak. Further investigation into the dysregulation of the immune system induced by tumor cells during development of NSCLC and additional results from ongoing studies will provide insight on how immunotherapy can be used to shift the balance of immune control away from a tumor-induced immune suppressive state to an active antitumor immune response.

ACKNOWLEDGMENTS

Professional medical writing assistance was provided by Mark Palangio at StemScientific, and Ashfield Company, and was funded by Bristol-Myers Squibb.

REFERENCES


52. Garon EB, Gandhi L, Rizvi N, et al. Antitumor activity of pembrolizumab (pembrolizumab; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients with advanced NSCLC. Presented at the European Society for Medical Oncology Congress, Madrid, Spain, September 26–30, 2014 (abstract LBA43).


